What the FDA labels say about taking them together
Atazanavir and ethinyl estradiol/segesterone
Ethinyl estradiol/segesterone's FDA label of April 23, 2025 names atazanavir in its drug interactions section; the atazanavir labels PlainMeds reads (2) do not name ethinyl estradiol/segesterone. The ethinyl estradiol/segesterone label: “In contrast, significant increases in systemic exposure of estrogen and/or progestin have been noted when CHCs are co-administered with certain other HIV protease inhibitors and with other non-nucleoside reverse …”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the ethinyl estradiol/segesterone FDA label on DailyMed (effective April 23, 2025).
What does the atazanavir label say about ethinyl estradiol/segesterone?
Atazanavir's label (effective August 6, 2025) and its 1 other brand-application label do not name ethinyl estradiol/segesterone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the ethinyl estradiol/segesterone label say about atazanavir?
Ethinyl estradiol/segesterone label, drug interactionsIn contrast, significant increases in systemic exposure of estrogen and/or progestin have been noted when CHCs are co-administered with certain other HIV protease inhibitors (eg, indinavir and atazanavir/ritonavir) and with other non-nucleoside reverse transcriptase inhibitors (eg, etravirine).
Source: FDA drug label (Annovera), Mayne Pharma, effective April 23, 2025 (SPL set eb18194f-2021-41fa-8bdf-31e0c0eb646b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Ethinyl estradiol/segesterone | |
|---|---|---|
| Labeled for | HIV | Birth control |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $2,315.29 per ring Annovera vaginal ring |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once